Castle Biosciences, Inc. filings document the regulatory record for a Delaware molecular diagnostics company with common stock listed on the Nasdaq Global Market under CSTL. Recent Form 8-K filings report quarterly and annual operating results, preliminary performance updates, and Regulation FD slide presentations tied to management communications.
The company’s proxy materials cover annual meeting matters, executive compensation, director elections, stockholder voting procedures, and governance disclosures. Other material-event filings document amendments to bylaws, including provisions related to stockholder meetings, director nominations, and board governance, alongside standing disclosures on registered securities and exchange listing status.
CASTLE BIOSCIENCES INC (CSTL) reported that Chief Commercial Officer Juvenal Tobin W sold 1,730 shares of common stock on August 17, 2026 in an open-market or private transaction at a weighted-average price of $29.59 per share, under a Rule 10b5-1 trading plan adopted on December 10, 2025. The trades occurred in multiple lots between $29.21 and $30.01 per share, and Tobin now directly holds 75,964 shares of CSTL common stock.
CASTLE BIOSCIENCES INC (CSTL) reported that its Chief Financial Officer, Frank Stokes, sold common stock in an open-market transaction. On 2026-08-14, he sold 24,908 shares at a weighted-average price of $29.77 per share, executed in multiple trades between $29.71 and $29.97. Following this sale, he directly holds 35,177 shares of Castle Biosciences common stock.
CASTLE BIOSCIENCES INC (CSTL) CEO Derek J. Maetzold reported an option exercise and related share sales. He exercised a stock option for 1,100 shares of common stock at $2.39 per share, receiving 1,100 shares that were then sold at $30.02 per share. Additional sales totaling 7,232 shares of common stock were made by several trusts for which he or his spouse serves as trustee or beneficiary, at the same weighted-average price. After these transactions, he holds 37,757 shares directly, and various family and grantor retained annuity trusts hold between 11,534 and 40,935 shares each. All trades were made under a Rule 10b5-1 plan adopted on December 3, 2025, and the option shares exercised were fully vested.
A holder of CSTL common stock filed a notice of intent to sell up to 24,908 shares through Morgan Stanley Smith Barney LLC Executive Financial Services on 08/14/2026, with the shares listed on NASDAQ. The shares have an indicated aggregate market value of $741,493.72. They stem from restricted stock originally acquired from the issuer on several dates, including 8,082 shares on 12/09/2025, 6,644 shares on 03/04/2026, 3,412 shares on 12/10/2025, and 6,770 shares on 03/04/2026, all for cash. Shares outstanding were 30,549,507; this is a baseline figure, not the amount being sold.
The filing reports a planned sale of 25,792 shares of common stock, with an indicated market value of $763,959.04, to be effected through Goldman Sachs & Co. LLC on or about 08/14/2026 on the NASD market.
It also lists numerous recent sales of common shares by Derek Maetzold and several related family trusts between May and August 2026, including individual transactions of several thousand shares each, some following a cashless exercise / same-day sale of stock options granted as compensation.
Castle Biosciences Inc Chief Commercial Officer Juvenal Tobin W reported selling 1,301 shares of common stock on 2025-11-24 at $38.39 per share in an open-market or private transaction. Following the sale, he directly holds 77,694 shares. The trade was executed under a Rule 10b5-1 plan adopted on September 11, 2024.
Castle Biosciences (CSTL) president and CEO Derek J. Maetzold reported option exercises and related share sales on August 4–5, 2026. He exercised options covering 22,902 common shares at $2.39 per share, then he and related family trusts sold a combined 39,016 shares at weighted-average prices around $30.68–$31.34 per share. These transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2025.
Castle Biosciences chief operating officer Kristen M. Oelschlager reported selling a total of 8,586 shares of common stock on August 3, 2026, in three open-market transactions at weighted-average prices of $29.12, $30.00 and $30.62 per share, each executed across multiple trades within disclosed price ranges. These sales were made pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026, indicating they were pre-scheduled. Oelschlager also has indirect ownership of 97,251 shares held by The Fritz Shorter Trust, where she and her spouse serve as trustees and beneficiaries.
Castle Biosciences Inc Chief Commercial Officer Juvenal Tobin reported open‑market or private sales totaling 19,040 shares of common stock in four transactions on July 31 and August 3, 2026. The shares were sold at weighted‑average prices ranging from $28.2500 to $30.2640 per share under a Rule 10b5‑1 trading plan adopted on December 10, 2025.
CASTLE BIOSCIENCES INC president and CEO Derek J. Maetzold exercised stock options and sold common shares under a Rule 10b5-1 trading plan adopted on December 3, 2025. On July 31 and August 3, 2026 he exercised options covering 17,144 shares at $2.39 per share and sold an aggregate 28,646 shares at weighted-average prices of $30.152 and $30.353, respectively, including sales by The Maetzold Descendants 2020 Trust and the Derek Maetzold 2020 Irrevocable Trust. The options exercised were fully vested, and he continues to report indirect holdings through several family trusts.